Research articles

Medical research scientists are working around Australia and the globe to better understand neurological disorders and their causes, seeking new or better treatments and ultimately, cures. Here are details of current research projects and exciting discoveries in the field of neurological research.

MSWA recommends that you discuss any research results, or new treatments mentioned, with your neurologist; as they know your individual circumstances and can provide personalised advice.

13-year data finds Tecfidera safe and reduces RRMS relapses

Long-term treatment with Tecfidera (dimethyl fumarate) continues to be safe and effective at reducing the frequency of relapses and disability progression in patients with relapsing-remitting multiple sclerosis (RRMS).

Read MS News Today's article

Major study into MS and pregnancy

New findings suggest delayed and reduced rates of pregnancy globally are likely associated with increased incidence of MS amongst women of a childbearing age.

Read MS Research Australia's article

First treatment for an MS-like disease

The TGA has approved the first ever treatment – eculizumab (Soliris) – for an MS-like disease known as neuromyelitis optica spectrum disorder (NMOSD).

MS Research Australia is advocating for the new treatment to be included on the PBS.

Read MS Research Australia's article

International collaboration to accelerate clinical trials for progressive MS

The International Progressive MS Alliance has convened a panel of experts to evaluate the potential of ‘neurofilament light’ (NfL) as a way to easily and reliably track MS progression.

MSWA is proud to support the International Progressive Alliance through an allocation in our MSRA funding.

Read MS Australia's full article

Help MS research by participating in an Australian trial

Want to be part of the research? Find an MS trial to get involved in!

Find out more Find an MS trial in your region

MIST AHSCT trial results published

A treatment used for cancer, autologous haematopoietic stem cell transplant (AHSCT) has been used to treat MS for many years. A study has been ongoing from 2005 to 2016 to compare AHSCT with other MS therapies.

The results of this trial, which were published in January 2019, showed that some patients receiving AHSCT had improvements in disability scores and significantly fewer relapses compared to those on standard MS medications.

Read MS Research Australia's article

Anti EBV trial shows promise in progressive MS

Professor Michael Pender and Professor Rajiv Khanna, of the QIMR Berghofer Medical Research Institute in Brisbane, have completed a small trial using adoptive T-cell immunology to target Epstein-Barr virus-infected B cells. Seven of 10 participants showed clinical improvements including reduction in disability and improvements in fatigue.

Read MS Research Australia's article

Mavenclad® tablets approved on the PBS

From 1 January 2019 people eligible for MAVENCLAD® for RRMS will pay a maximum of $39.50 per script, or $6.40 for concessional patients. Mavenclad® is used to treat people with relapsing remitting MS.

Read MS Australia's article

Herbicide found to trigger inflammation in MS

A study by researchers at Brigham and Women’s Hospital in Boston, Massachusetts, has found that that herbicide linuron, may be an important environmental risk factor in the development of neurological diseases that include multiple sclerosis.

Read Beyond Pesticides' article

Get in touch

If you would like more information about specific research, you can email us at

Click here to read the latest edition of Vitality – MSWA's monthly e-newsletter covering the latest articles of research, medical advancements and general wellbeing for people living with MS.